Latest Haemophilia Stories
-- Using Mutant Protein, CHOP Hematologist Safely Removes Unwanted Antibodies, Reverses Hemophilia in Dog Model of Bleeding Disease -- PHILADELPHIA, March 13, 2015 /PRNewswire-USNewswire/
WHIPPANY, N.J., March 4, 2015 /PRNewswire/ -- Bayer HealthCare today announced that the U.S.
CSL Behring Pioneered Donations to WFH Program; Further Underscores Commitment to Providing Global Bleeding Disorders Community with Access to Treatment KING OF PRUSSIA, Pa., Feb.
DEERFIELD, Ill., Feb. 11, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc.
CSL Behring Achieves Another Key Milestone in PROLONG-9FP, its Recombinant Factor IX Fusion Protein Development Program; Continues to Advance CSL Behring's Legacy of Improving Patient Well-Being
Researchmoz added new research report on Recombinant Coagulation Factors Pipeline Analysis to 2015 to its huge collection. Albany, NY (PRWEB) February 01, 2015
DUBLIN, January 27, 2015 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/pfd99m/recombinant) has announced the addition of the "Recombinant
WHIPPANY, N.J., Dec. 17, 2014 /PRNewswire/ -- Bayer HealthCare has submitted a Biologics License Application (BLA) to the U.S.
CSL Behring Continues Improving Patient Well-Being; Key Milestone Achieved in PROLONG-9FP, Company's Recombinant Factor IX Fusion Protein Development Program KING OF PRUSSIA,
Leading gene therapy Company will partner with established market leader to develop a potential new treatment paradigm for hemophilia B PHILADELPHIA, Dec.
- A young chicken: also used as a pet name for children.